Factors Affecting Medication Adherence to Topical Acne Medications: a Single-center, Prospective Study Evaluating the Adherence and Patient Satisfaction to Single and Multiple Topical Acne Medications

Acne is a chronic condition that typically requires the use of multiple medications.1 Medication adherence is especially challenging for patients with chronic diseases and often decreases over time, especially for those using topical medications.1 Nonadherence can result in multiple negative effects including treatment failure, increased healthcare costs, and decreased quality of life. Primary nonadherence refers to problems acquiring and starting treatment. Challenges to this form of nonadherence include a lack of knowledge, misunderstanding of usage, poor communication with provider, increased cost, and fear of side effects.2 Secondary nonadherence refers to when the patient does not use the medication as prescribed. Hurdles to secondary nonadherence include delayed results, increased complexity of treatment plan, adverse effects, busy lifestyle, and inconvenience.2

Start Date15 Feb 2024

Sponsor / Collaborator

Wake Forest School of Medicine

[+1]

EUCTR2018-004338-13-NL / Unknown statusPhase 4IIT

Short term clinical efficacy of topical treatment with clindamycin-benzoyl peroxide gel compared with clindamycin lotion in mild to moderate Hidradenitis Suppurativa - TOPIC

Start Date11 Jun 2019

Sponsor / Collaborator-

NCT03257202 / CompletedPhase 2IIT

Cutibacterium Acnes Persists Despite Topical Clindamycin and Benzoyl Peroxide

This study is about preventing surgical site infections of the shoulder. We hope to learn if clindamycin alone, benzoyl peroxide alone, or clindamycin and benzoyl peroxide together can affect growth of Propionibacterium acnes in the dermal layer.

Start Date11 Sep 2017

Sponsor / Collaborator

University of Southern California

100 Clinical Results associated with Benzoyl Peroxide/Clindamycin Phosphate

100 Translational Medicine associated with Benzoyl Peroxide/Clindamycin Phosphate

100 Patents (Medical) associated with Benzoyl Peroxide/Clindamycin Phosphate

247

Literatures (Medical) associated with Benzoyl Peroxide/Clindamycin Phosphate

22 Mar 2024·Biomedical Research

Indoxyl sulfate contributes to colorectal cancer cell proliferation and increased EGFR expression by activating AhR and Akt

Article

Author: Yano, Shozo ; Ichisaka, Yu ; Nishimura, Kohji ; Niwa, Toshimitsu ; Shimizu, Hidehisa

Although patients with chronic kidney disease (CKD) have a higher risk of colorectal cancer (CRC) aggravation, the connection between these two diseases is not well understood. Recent studies have shown that both CKD and CRC aggravation are closely related to an increased abundance of indole-producing Fusobacterium nucleatum in the gut. The indole absorbed from the gut is eventually metabolized to indoxyl sulfate in the liver. Since indoxyl sulfate is involved not only in accelerating CKD progression but also in the initiation and development of its associated complications, the present study aimed to clarify whether indoxyl sulfate induces the proliferation of CRC cells. This study found that indoxyl sulfate induced the proliferation of CRC-derived HCT-116 cells by activating the aryl hydrocarbon receptor (AhR) and the proto-oncogene Akt. The AhR antagonist CH223191 and Akt inhibitor MK2206 suppressed indoxyl sulfate-induced proliferation of HCT-116 cells. We also found that indoxyl sulfate upregulated epidermal growth factor receptor (EGFR) expression, which is associated with poor prognosis of CRC, whereas CH223191 and MK2206 repressed EGFR expression. Furthermore, indoxyl sulfate increased the sensitivity of CRC cells to EGF by upregulating EGFR expression. These findings suggest that indoxyl sulfate may be an important link between CKD and CRC aggravation.

01 Jan 2024·Neuroscience Letters

Effects of the uremic toxin indoxyl sulfate on seizure activity, learning and brain oxidative stress parameters in mice

Article

Author: Raszewski, Grzegorz ; Łukawski, Krzysztof ; Czuczwar, Stanisław J

Patients with end-stage renal disease often have neurological disorders, with a higher incidence of memory impairment or epilepsy than in the general population. Patients undergoing hemodialysis are particularly exposed to the biological effects of uremic toxins. Indoxyl sulfate (IS) is one of the most potent uremic toxins; however, its possible effects on seizure susceptibility or memory functions have yet to be elucidated. In the current study, we focused on investigating the possible convulsant and amnesic effects of IS in recognized animal models. The study was performed on adult male Swiss mice. IS and scopolamine (SCO) were administered intraperitoneally (i.p.), and pentylenetetrazole (PTZ) was injected subcutaneously (s.c.). All substances were given as single injections. Acute IS administration (400 mg/kg) led to its accumulation in the brain. IS at doses of 200 and 400 mg/kg decreased the PTZ convulsive threshold, and at the same doses, it did not significantly affect the threshold for electroconvulsions. IS (200 and 400 mg/kg) did not impair learning in the passive avoidance test and did not increase the SCO-induced memory impairment in this test. IS increased lipid peroxidation, decreased the level of reduced glutathione, and reduced the activity of superoxide dismutase and catalase in mouse brains. Exposure to IS did not significantly change the activity of acetylcholinesterase in the brain tissue. This study shows that acute exposure to IS induces oxidative stress in the brain and potentiates PTZ-induced seizures in mice. Further studies are needed to find out whether IS-induced oxidative stress may affect epileptic seizures and/or epileptogenesis.

20 Dec 2023·Nephrology Dialysis Transplantation

Indoxyl sulfate inhibits muscle cell differentiation via Myf6/MRF4 and MYH2 downregulation

Article

Author: McKay, Nathalie ; Beau, Alice ; Burtey, Stéphane ; Bartoli, Marc ; Dou, Laetitia ; Chermiti, Rania ; Bataille, Stanislas ; Aniort, Julien ; Da Silva, Nathalie ; Poitevin, Stéphane ; Koppe, Laetitia ; Benoit, Bérengère

ABSTRACTBackgroundChronic kidney disease (CKD) is associated with a significant decrease in muscle strength and mass, possibly related to muscle cell damage by uremic toxins. Here, we studied in vitro and in vivo the effect of indoxyl sulfate (IS), an indolic uremic toxin, on myoblast proliferation, differentiation and expression of myogenic regulatory factors (MRF)—myoblast determination protein 1 (MyoD1), myogenin (Myog), Myogenic Factor 5 (Myf5) and myogenic regulatory factor 4 (Myf6/MRF4)—and expression of myosin heavy chain, Myh2.MethodsC2C12 myoblasts were cultured in vitro and differentiated in myotubes for 7 days in the presence of IS at a uremic concentration of 200 µM. Myocytes morphology and differentiation was analyzed after hematoxylin-eosin staining. MRF genes’ expression was studied using reverse transcription polymerase chain reaction in myocytes and 5/6th nephrectomized mice muscle. Myf6/MRF4 protein expression was studied using enzyme-linked immunosorbent assay; MYH2 protein expression was studied using western blotting. The role of Aryl Hydrocarbon Receptor (AHR)—the cell receptor of IS—was studied by adding an AHR inhibitor into the cell culture milieu.ResultsIn the presence of IS, the myotubes obtained were narrower and had fewer nuclei than control myotubes. The presence of IS during differentiation did not modify the gene expression of the MRFs Myf5, MyoD1 and Myog, but induced a decrease in expression of Myf6/MRF4 and MYH2 at the mRNA and the protein level. AHR inhibition by CH223191 did not reverse the decrease in Myf6/MRF4 mRNA expression induced by IS, which rules out the implication of the ARH genomic pathway. In 5/6th nephrectomized mice, the Myf6/MRF4 gene was down-regulated in striated muscles.ConclusionIn conclusion, IS inhibits Myf6/MRF4 and MYH2 expression during differentiation of muscle cells, which could lead to a defect in myotube structure. Through these new mechanisms, IS could participate in muscle atrophy observed in CKD.

News (Medical) associated with Benzoyl Peroxide/Clindamycin Phosphate

16 Jul 2024

·www.drugs.com

'Staying Regular' Is Good for Good Health

TUESDAY, July 16, 2024 -- Being regular is good for you, a new study shows. Predictable bowel movements could be tied to your long-term health, allowing your body to absorb essential nutrients without producing harmful organ-damaging toxins, researchers found. The “Goldilocks zone” of bowel movement frequency, once or twice a day, is associated with better health, results show. That gives gut microbes enough time to digest dietary fiber, which they ferment into beneficial short-chain fatty acids, explained lead researcher Johannes Johnson-Martinez , a doctoral student with the Institute for Systems Biology in Seattle. “After that, the ecosystem switches to fermentation of proteins, which produces several toxins that can make their way into the bloodstream,” Johnson-Martinez explained in an institute news release. For the study, researchers analyzed medical and lifestyle data for more than 1,400 healthy adults, according to the study published July 16 in the journal Cell Reports Medicine. These folks were divided into four groups based on bowel movement frequency -- constipation , low-normal, high-normal and diarrhea . The constipated moved their bowels once or twice a week, low-normal three to six times a week, and high-normal one to three times a day. People with constipation and diarrhea tend to have higher levels of bacteria associated with toxic protein fermentation, results showed. The toxins produced by protein fermentation can cause organ damage, the researchers added. For example, a protein fermentation byproduct called indoxyl-sulfate is significantly associated with reduced kidney function, results show. Blood levels of that byproduct and another toxin called p-cresol-sulfate were elevated in people with constipation. Meanwhile, other toxins associated with liver damage were higher in people with diarrhea. “Chronic constipation has been associated with neurodegenerative disorders and with chronic kidney disease progression in patients with active disease,” said researcher Sean Gibbons , an associate professor with the Institute for Systems Biology. “However, it has been unclear whether or not bowel movement abnormalities are early drivers of chronic disease and organ damage, or whether these retrospective associations in sick patients are merely a coincidence,” Gibbons added. “Here, in a generally healthy population, we show that constipation, in particular, is associated with blood levels of microbially derived toxins known to cause organ damage, prior to any disease diagnosis.” Not surprisingly, people tend to be in the Goldilocks zone if they eat a fiber-rich diet, drink lots of water, and have regular exercise, researchers said. Younger people, women and those with a lower BMI tend to have less frequent bowel movements, results show. Mental health also can affect a person’s bowel movements, results show. “Overall, this study shows how bowel movement frequency can influence all body systems, and how aberrant bowel movement frequency may be an important risk factor in the development of chronic diseases,” Gibbons said. “These insights could inform strategies for managing bowel movement frequency, even in healthy populations, to optimize health and wellness.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

13 Sep 2022

·www.biospace.com

Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director

WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Gerard DiGirolamo as National Sales Director. In this newly created position, Mr. DiGirolamo will report to Mark Baldyga, Biofrontera’s Head of Sales & Marketing, and will help execute the Company’s U.S. sales division and objectives including the strategic design, expansion and leadership of its sales team. He will oversee recruiting and staffing to support Ameluz®, BF-RhodoLED® and Xepi® commercial efforts, as well as spearhead planning for the launch of BF-RhodoLED XL®. Mr. DiGirolamo brings to Biofrontera more than 25 years of experience in building pharmaceutical sales and commercial teams with a particular expertise in dermatology. Most recently he served as Vice President of Sales at Verrica Pharmaceuticals, a medical dermatology company where he built their U.S. sales infrastructure in preparation for a commercial launch of its drug-device combination product for the treatment of molluscum contagiosum. This provides valuable experience for working with Biofrontera’s combination of Ameluz® and the RhodoLED® lamps. “Gerard’s insight and understanding of the dermatology market, along with the many relationships he’s cultivated within our industry will be extremely valuable in working with Mark Baldyga on the successful implementation of our commercial strategy. His approach involving collaborating with medical affairs, marketing, key opinion leaders and national influencers through advisory boards and conferences fully aligns with our mission. He is passionate about building cohesive and collaborative teams that have led to successful product launches and market-share gains. We are delighted to have Gerard lead our commercial team and welcome him to Biofrontera,” stated Erica Monaco, Chief Executive Officer of Biofrontera Inc. “I’m proud to join Biofrontera and to support their commitment to dermatological innovation. With my experience in building and supporting teams at national and regional levels, I look forward to leveraging my networks to position Ameluz-PDT as the first-choice treatment for actinic keratosis and establishing the optimal commercial infrastructure for a successful launch of BF-RhodoLED XL®,” stated Mr. DiGirolamo. Prior to Verrica Pharmaceuticals, Mr. DiGirolamo was a Field Vice President at GlaxoSmithKline (GSK) and previously spent 16 years with Stiefel, now part of GSK. At GSK he worked with multiple dermatology brands and exceeded sales forecasts including for the launch of Fabior Foam®, a treatment for psoriasis and acne. As Executive National Account Manager at Stiefel he led negotiations with national managed care organizations, securing unrestricted access to the acne therapy Duac CS™ and coverage of the seborrheic dermatitis therapies Extina™ and Xologel™. Prior to Stiefel, he was an Area and District Sales Manager at Novartis. Mr. DiGirolamo holds a B.A. from Rutgers University. About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit . Forward-Looking Statements Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company’s business and marketing strategy, future operations and business, potential to expand the label of Ameluz®, market presence and position of Ameluz® and ongoing clinical trials conducted by our licensing partners and the future impact of such trials on the market for Ameluz®. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of extraordinary external events, such as the current COVID-19 pandemic; any changes in the Company’s relationship with its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED® in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz® in combination with BF-RhodoLED® is consistent with the Company’s expectations; the Company’s ability to complete the transition to a public company; the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed in the Company’s filings with the SEC, which can be obtained on the SEC website at . Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. Contacts: Biofrontera Inc. Anke zur Mühlen +1 781 486 1539 us-ir@biofrontera.com LHA Investor Relations Tirth T. Patel +1 212 201 6614 tpatel@lhai.com # # #

100 Deals associated with Benzoyl Peroxide/Clindamycin Phosphate

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	D10AE51	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pustular acne	AU	Glaxosmithkline Australia Pty Ltd.	30 Jan 2006
Acne Vulgaris	US	Bausch Health Americas, Inc.	21 Dec 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acne Vulgaris	Preclinical	CA	Dow Pharmaceutical Sciences, Inc.	01 Oct 2006
Acne Vulgaris	Preclinical	BZ	Dow Pharmaceutical Sciences, Inc.	01 Oct 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01796665 (CTgov)	Phase 3	Acne Vulgaris	1,180	Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% (Test Product)	jxgvgftobb(ehiptjeikv) = hlhthhhjra zrlswifwhu (yfsrkaqeua, tfnzjthcjx - syouvyjctl) View more	-	20 Jan 2021
				Acanya Gel (Reference Product)	jxgvgftobb(ehiptjeikv) = acwnggtjdi zrlswifwhu (yfsrkaqeua, qptpjazvuq - vhogfbohlz) View more
NCT03122457 (CTgov)	Phase 2	Actinic Keratosis	22	lidamycin phosphate+benzoyl peroxide 1.2%/3.75% combination	tntkzboxat(mmcemlgwwr) = wbapewjxcc yryyvnbcwz (ctzspquagx, bvhhywabjl - oqzmmbqmgw) View more	-	04 Sep 2020
NCT01237821 (CTgov)	Not Applicable	Acne Vulgaris	66	Effaclar (Effaclar)	lpzoudtcbd(tyklbutosv) = ovxwloupcm dhpvaslywy (qkxppflcmu, ajoilsxxft - tsstruezfs) View more	-	16 Jul 2019
				BenzaClin (Benzaclin)	lpzoudtcbd(tyklbutosv) = qtlxkkbxqx dhpvaslywy (qkxppflcmu, qhvzczpsvb - xeqklgsgkb) View more
NCT03402893 (CTgov)	Phase 4	Hyperpigmentation \| Acne Vulgaris	21	ONEXTON Topical Gel	xprslcindi(smnkjcznff) = otqtohxved mkngnkxxev (yeazbhymqq, ymcalzlypd - gehvwhipey) View more	-	19 Feb 2019
NCT01445301 (115287, CTgov)	Phase 3	Acne Vulgaris	800	GSK2585823 (GSK2585823 Once Daily)	eaautiphjo(egackyunfm) = wlzazcmlok aascndthrs (oifucroszy, fxvujlmbhw - ihfdponnip) View more	-	27 Apr 2018
				GSK2585823 (GSK2585823 Twice Daily)	eaautiphjo(egackyunfm) = upexchnglt aascndthrs (oifucroszy, asoppkqgcf - torbbmtmop) View more
NCT02058628 (CTgov)	Phase 4	Acne Vulgaris	222	DUAC (DUAC®)	khidegkdac(sojftdjezj) = tcpjvfjdgd exeofrawtu (lnkixirhsp, fhyyzjfhhy - gcrofniibu) View more	-	25 Aug 2017
				SKINOREN (SKINOREN®)	khidegkdac(sojftdjezj) = zmhvgmfknv exeofrawtu (lnkixirhsp, ssdxsawsln - oxuhtgqudy) View more
NCT00671749 (CTgov)	Phase 4	Acne Vulgaris	100	Differin+Duac	pfmhbuhfdf(kikwcorwjq) = jeuihufwna bbbqozecld (qubzxkspbm, bjrqdlbgux - xooxsvfmir) View more	-	16 Mar 2016
NCT01915732 (CTgov)	Phase 3	Acne Vulgaris	1,018	Duac (Duac Once Daily Gel)	ojwivgsnlj(bplllzoict) = fsnbingidq dgghvzzfad (rhksrdbexe, hjypnwrcso - iudcffobkt) View more	-	25 Nov 2014
				Dalin+clindamycin phosphate+clindamycin (Dalin Gel)	ojwivgsnlj(bplllzoict) = bvgnvwxhje dgghvzzfad (rhksrdbexe, udlxlhnfss - vkhqvhyyws) View more
NCT01044264 (CTgov)	Not Applicable	Acne Vulgaris	602	1% Clindamycin/5% Benzoyl Peroxide Topical Gel (1% Clindamycin/5% Benzoyl Peroxide Topical Gel)	jsjdckahue(mxcxfokhyp) = ddntgqjjwu hbxtmvqozm (uebxihygan, mpisyroevi - rcydffdeyx) View more	-	17 Dec 2012
				1% Clindamycin/5% Benzoyl Peroxide Topical Gel (DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel)	jsjdckahue(mxcxfokhyp) = xjgarjrbub hbxtmvqozm (uebxihygan, ofdwabfycs - zcxbzuxxck) View more
NCT00807014 (CTgov)	Phase 4	Acne Vulgaris	169	Duac Gel (Duac Gel)	kgsygwvqlb(wovcbvsrtr) = nbjeckruei zjpjeqhfmd (jtnnzrmmww, bbshfvfvue - stcjjqrpjm) View more	-	06 Mar 2012
				Differin gel (Differin Gel)	kgsygwvqlb(wovcbvsrtr) = vzilegfrsw zjpjeqhfmd (jtnnzrmmww, hxkrufuwhv - ymrbpdiwjw) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis